Staff Profile

Dr Helen Lachmann

Photo

Personal Profile

Name: Helen Lachmann Email: h.lachmann@ucl.ac.uk
Title: Dr Tel: 442074332820
Department: Inflammation Fax: 4.4207433282e+011
Position: Senior Clinical Lecturer Address: UK National Amyloidosis Centre, UCLMS, Royal Free Campus, Rowland Hill Street, London, NW3 2PF
Research Domain: Infection Immunology & Inflammation Web Page:  

Profile

Research Description

My research has a predominantly clinical focus, notably including phenotypic characterisation and studies into the treatment of acquired and hereditary forms of systemic amyloidosis and the use of novel therapies in inherited periodic fever syndromes.

Research Activities

Amyloidosis, the inherited fever syndromes

Education Description

Largely postgraduate level

UCL Collaborators

External Collaborators

Publications

    2012

    • Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.. Blood, 119(19), 4387 - 4390. doi:10.1182/blood-2011-10-388462
    • Dungu J, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Venner CP, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson L (2012). Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis.. J Cardiovasc Magn Reson, 14 Suppl 1, O87 - . doi:10.1186/1532-429X-14-S1-O87
    • Toplak N, Frenkel J, Ozen S, Lachmann HJ, Woo P, Koné-Paut I, De Benedetti F, Neven B, Hofer M, Dolezalova P, Kümmerle-Deschner J, Touitou I, Hentgen V, Simon A, Girschick H, Rose C, Wouters C, Vesely R, Arostegui J, Stojanov S, Ozgodan H, Martini A, Ruperto N, Gattorno M, for the Paediatric Rheumatology International Trials Organisation (PRINTO), Eurotraps and Eurofever Projects (2012). An International registry on Autoinflammatory diseases: the Eurofever experience.. Ann Rheum Dis, , - . doi:10.1136/annrheumdis-2011-200549
    • Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2012). Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.. Eur Heart J, 33(9), 1120 - 1127. doi:10.1093/eurheartj/ehr383

    2011

    • Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie KS, Jiménez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann HJ (2011). Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.. Ann Rheum Dis, 70(12), 2095 - 2102. doi:10.1136/ard.2011.152728
    • Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT, Pinney JH, Hawkins PN, Gillmore JD (2011). Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.. Am J Pathol, 179(4), 1978 - 1987. doi:10.1016/j.ajpath.2011.06.024
    • Lane T, Lachmann HJ (2011). The emerging role of interleukin-1β in autoinflammatory diseases.. Curr Allergy Asthma Rep, 11(5), 361 - 368. doi:10.1007/s11882-011-0207-6
    • Lachmann HJ (2011). Clinical immunology review series: An approach to the patient with a periodic fever syndrome.. Clin Exp Immunol, 165(3), 301 - 309. doi:10.1111/j.1365-2249.2011.04438.x
    • Pinney JH, Lachmann HJ, Gillmore JD, Wechalekar A, Gibbs SDJ, Sattianayagam P, Banypersad SM, Dungu J, Wassef N, McCarthy CA, Hawkins PN, Whelan CJ (2011). SENILE SYSTEMIC AMYLOIDOSIS: A COMMON CAUSE OF HEART FAILURE IN THE ELDERLY?. doi:10.1136/heartjnl-2011-300198.103
    • Sattianayagam P, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Philip HN, Rowczenio DM, Gilbertson JA, Gillmore JD (2011). The Role of Liver Transplantation in Hereditary Non-Neuropathic Systemic Amyloidosis.
    • Eleftheriou D, Ho A, Standing A, Klein NJ, Lachmann HJ, Hawkins PN, Woo P, Brogan PA (2011). PFAPA syndrome and increased levels of IgD-a distinct clinical phenotype?. CLIN EXP RHEUMATOL, 29(2), 455 - 456.
    • Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN (2011). Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis.. Haematologica, 96(7), 1079 - 1080. doi:10.3324/haematol.2011.040493
    • Standing AS, Eleftheriou D, Lachmann HJ, Brogan PA (2011). Comment on: Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosa: reply.. Rheumatology (Oxford), 50(7), 1349 - 1350. doi:10.1093/rheumatology/ker170
    • Smith RM, Lachmann HJ, Jayne DRW (2011). IL-1 blockade for Schnitzler's syndrome.
    • Hawkins PN, Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Kone-Paut I, Hoyer J, Quartier P, Smith J, Gattorno M, Leslie K, Gul A, Widmer A, Patel N, Preiss R, Lachmann HJ (2011). CANAKINUMAB PROVIDES RAPID IMPROVEMENT WITH SUSTAINED CLINICAL AND INFLAMMATORY REMISSION IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME PATIENTS ACROSS ALL SEVERITY PHENOTYPES.
    • Lachmann HJ, Quartier P, Hachulla E, Gattorno M, Cartwright R, Kone-Paut I, Zulian F, Weisbarth-Riedel E, Lepore L, Hoyer J, Foeldvari I, Ramos E, Leslie K, Krammer G, Preiss R, Incera E, Kuemmerle-Deschner JB, Hawkins PN (2011). RAPID AND SUSTAINED TREATMENT EFFECT OF CANAKINUMAB IN CHILDREN ACROSS DIFFERENT DISEASE SEVERITY PHENOTYPES OF CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME.
    • Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SD, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2011). Outcome in renal Al amyloidosis after chemotherapy.. J Clin Oncol, 29(6), 674 - 681. doi:10.1200/JCO.2010.30.5235
    • Piram M, Frenkel J, Gattorno M, Ozen S, Lachmann HJ, Goldbach-Mansky R, Hentgen V, Neven B, Stojanovic KS, Simon A, Kuemmerle-Deschner J, Hoffman H, Stojanov S, Duquesne A, Pillet P, Martini A, Pouchot J, Koné-Paut I, EUROFEVER and EUROTRAPS networks (2011). A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference.. Ann Rheum Dis, 70(2), 309 - 314. doi:10.1136/ard.2010.132613
    • Lachmann HJ, Quartier P, So A, Hawkins PN (2011). The emerging role of interleukin-1β in autoinflammatory diseases.. Arthritis Rheum, 63(2), 314 - 324. doi:10.1002/art.30105
    • Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, Lheritier K, Patel N, Preiss R, Hawkins PN, Canakinumab in CAPS Study Group (2011). Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.. Arthritis Res Ther, 13(6), R202 - . doi:10.1186/ar3535
    • Lachmann HJ (2011). Treatment of Inflammasone-Related Disorders. In Pétrilli V (Ed.), The Inflammasomes (pp. - ). : Springer Basel AG.
    • Lachmann HJ (2011). Immunodeficiency disorders and orphan lung disease. In Palange P, Simonds AK (Ed.), ERS Handbook of Respiratory Medicine 2010 (pp. - ). : European Respiratory Society.
    • Pinney JH, Lachmann HJ (2011). Paraprotein-related renal disease and amyloid. Medicine, 39(8), 481 - 485.
    • Lachmann HJ, Meini A, Touitou I, Obici L, Finetti M, Minden K, Cantarini L, Desjonqueres M, Frenkel J, Kone-Paut I, Vougiouka O, Rua Elorduy MJ, Ruperto N, Woo P, Gattorno M (2011). Demographic and Genetic Results From the EUROFEVERS/EUROTRAPS Consortia in the Largest Series of Patients with TRAPS Yet Reported.
    • Sattianayagam PT, Gibbs SD, Rowczenio D, Pinney JH, Wechalekar AD, Gilbertson JA, Hawkins PN, Lachmann HJ, Gillmore JD (2011). Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation.. J Intern Med, , - . doi:10.1111/j.1365-2796.2011.02470.x

    2010

    • Lachmann HJ, Hawkins PN (2010). The Hereditary periodic Fever Syndromes. In Warrell DA, Cox TM, Firth JD (Ed.), Oxford Textbook of Medicine (pp. - ). : .
    • Lachmann HJ, Hawkins PN (2010). Amyloidosis and the Skin. In Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (Ed.), Fitzpatrick's Dermatology in General Medicine (pp. - ). : The McGraw-Hill Companies Inc.
    • Lachmann HJ, Hawkins PN (2010). Secondary AA Amyloidosis. In Gertz MA, Rajkumar VS (Ed.), Amyloidosis: (pp. - ). : Springer.
    • Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN (2010). Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases.
    • Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN (2010). Remarkable Efficacy of IL 1 Receptor Antagonist In Schnitzler's Syndrome a Series of 6 Cases.
    • Standing A, Eleftheriou D, Lachmann H, Brogan PA (2010). Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari Syndrome and polyarteritis nodosa. Rheumatology, In press, - .
    • Hunt T, Gilbertson JA, Lachmann HJ, Gillmore JD, Gibbs SDJ, Sattianayagam PT, Whelan CJ, Hawkins PN, Wechalekar AD (2010). Unraveling the clonal B cell disease underlying localised AL amyloidosis.
    • Wechalekar AD, Harding S, Lachmann HJ, Gillmore JD, Wassef NL, Thomas M, Gibbs SDJ, Sattianayagam P, Whelan CJ, Bradwell AR, Hawkins PN (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis.
    • Gibbs SDJ, Pinney JH, Sattianayagam PT, Wechalekar AD, Lane T, Rowczenio DM, Offer M, Gilbertson JA, Hunt T, Hawkins PN, Gillmore JD, Lachmann HJ (2010). Light chain deposition disease (LCDD): a case series of 24 patients.
    • Gibbs SDJ, Sattianayagam PT, Whelan CJ, De Cruz M, Abreu JM, Pinney JH, Pawarova B, Wassef NL, Lane T, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2010). Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment.
    • Whelan CJ, Pawarova B, De Cruz M, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Pinney JH, Gillmore JD, Wassef N, Hawkins PN, Wechalekar AD (2010). Changes in serum NT-proBNP correlate with changes in both systolic and diastolic function in AL amyloidosis.
    • Whelan CJ, Pawarova B, De Cruz M, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Pinney JH, Gillmore JD, Hawkins PN, Wechalekar AD (2010). Assessment of left ventricular wall thickness in cardiac amyloidosis by different imaging modalities.
    • Palladini G, Hawkins PN, Foli A, Lachmann HJ, Perlini S, Gillmore J, Merlini G, Wechalekar AD (2010). N-terminal pro natriuretic peptide type B ( NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure.
    • Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Lachmann HJ, Whelan CJ, Pinney JH, Hawkins PN, Gillmore JD (2010). Solid organ transplantation in AL amyloidosis.
    • Lane T, Foard DM, Wechalekar AD, Gibbs SDJ, Lachmann HJ, Sattianayagam PT, Pinney JH, Rannigan LG, Gillmore JD, Hawkins PN (2010). ALchemy - a nationwide study of chemotherapy for systemic AL amyloidosis in the UK.
    • Rowczenio DM, Lachmann HJ, Gibbs SDJ, Gilbertson JA, Hunt T, Russell TL, Sattianayagam PT, Trojer H, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2010). Experience of ATTR in a single centre: findings among 220 patients.
    • Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2010). Localised amyloid at injection sites derived from porcine and human insulin.
    • Rowczenio DM, Lachmann HJ, Gibbs SDJ, Gilbertson JA, Hunt T, Russell TL, Sattianayagam PT, Trojer H, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2010). Hereditary systemic amyloidosis associated with three novel apolipoprotein AI variants.
    • Gillmore JD, Cocks K, Gibbs SDJ, Sattianayagam P, Lane T, Lachmann HJ, Schey S, Cavenagh J, Oakervee H, Morgan G, Bourne S, Skinner E, Bell S, Booth G, Foard DM, Mehta A, Hawkins PN, Wechalekar AD (2010). UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design.
    • Wechalekar AD, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Perlini S, Whelan CJ, Hawkins PN, Palladini G (2010). N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis.
    • Gibbs SDJ, Gillmore JD, Sattianayagam PT, Lachmann HJ, Lane T, Goodman HJB, Offer M, Whelan CJ, Rowczenio DM, Hutt DF, Gilbertson JA, Hawkins PN, Wechalekar AD (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study.
    • Lachmann HJ, Gillmore JD, Wechalekar AD, Sattianayagam PT, Gibbs SDJ, Pinney JH, Goodman HJB, Offer M, Gallimore JR, Gilbertson JA, Hunt T, Gopaul D, Hutt DF, Hawkins PN (2010). Survival on dialysis and outcome after renal transplantation in AA amyloidosis.
    • Sattianayagam PT, Rowczenio DM, Gibbs SDJ, Trojer H, Russell TL, Pinney JH, Lachmann HJ, Wechalekar AD, Hawkins PN, Pepys MB, Gilbertson JA, Hunt T, Gillmore JD (2010). Natural history of hereditary lysozyme amyloidosis.
    • Dogan A, Theis JD, Vrana JA, Jimenez-Zepeda VH, Lacy MQ, Leung N, Dispenzieri A, Zeldenrust SR, Fonseca R, Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Rowczenio D, Hawkins PN, Gillmore JD (2010). Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2).
    • Sattianayagam PT, Hahn A, Gibbs SDJ, Whelan CJ, Rowczenio DM, Trojer H, Russell TL, Pinney JH, Lachmann HJ, Wechalekar AD, Hawkins PN, Gilbertson JA, Hunt T, Gillmore JD (2010). Phenotype and natural history of transthyretin alanine 60 ( T60A) amyloidosis.
    • Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SDJ, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2010). Clinical outcome of systemic AL amyloidosis affecting the kidneys.
    • Hutt DF, Lane T, Gillmore JD, Lachmann HJ, Gibbs SDJ, Sattianayagam PT, Gopaul D, Quigley AM, Hawkins PN, Wechalekar AD (2010). Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis.
    • Sattianayagam PT, Gibbs SDJ, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD (2010). Solid Organ Transplantation in AL Amyloidosis. AM J TRANSPLANT, 10(9), 2124 - 2131. doi:10.1111/j.1600-6143.2010.03227.x
    • Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Kone-Paut I, Hoyer J, Smith J, Leslie K, Patel N, Preiss R, Hawkins PN (2010). EFFICACY AND SAFETY OF CANAKINUMAB IN A LARGE COHORT OF PATIENTS ACROSS DIFFERENT SEVERITY PHENOTYPES OF CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME (CAPS). JCR-J CLIN RHEUMATOL, 16(3), S93 - S93.
    • Leslie KS, Kuemmerle-Deschner JB, Lachmann HJ, Hachulla E, Hoyer J, Smith J, Kone-Paut I, Braun I, Widmer A, Patel N, Preiss R, Hawkins PN (2010). Efficacy and safety of Canakinumab (ILARIS (R)) in Cryopyrin-Associated Periodic Syndrome (CAPS): Interim results of an onging phase III study.
    • Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie K, Hachulla E, Quartier P, Ferreira A, Patel N, Lheritier K, Preiss R, Hawkins P (2010). IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC FEVER SYNDROME (CAPS) AFTER TREATMENT WITH CANAKINUMAB-A FULLY HUMAN ANTI-IL-1 beta MONOCLONAL ANTIBODY.
    • Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Hoyer J, Smith J, Leslie K, Kone-Paut I, Braun J, Widmer A, Patel N, Preiss R, Hawkins PN (2010). Spondyloarthropathies (Including Psoriatic Arthritis) [40-69]. doi:10.1093/rheumatology/keq716
    • Gillmore JD, Lachmann HJ, Wechalekar A, Hawkins PN (2010). Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation.. Blood, 115(21), 4313 - . doi:10.1182/blood-2010-01-261750
    • Lachmann HJ, Gillmore JD (2010). Renal amyloidosis.. Br J Hosp Med (Lond), 71(2), 83 - 86.
    • Gibbs SDJ, Sattianayagam PT, Pinney JH, Gilbertson JA, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2010). Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non-AL forms of the disease. INTERN MED J, 40(2), 167 - 168. doi:10.1111/j.1445-5994.2009.02127.x
    • Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB (2010). Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.. Br J Haematol, 148(5), 760 - 767. doi:10.1111/j.1365-2141.2009.08036.x
    • Kitley JL, Lachmann HJ, Pinto A, Ginsberg L (2010). Neurological manifestations of the cryopyrin-associated periodic syndrome. Neurology, 74(16), 1267 - 1270.

    2009

    • Sattianayagam P, Gibbs SD, Wechalekar A, Gilbertson JA, Lachmann HJ, Philip HN, Gillmore JD (2009). Systemic AA Amyloidosis in Crohn's Disease (CD): A Serum Amyloid P Component (SAP) Scintigraphy Study.
    • Sattianayagam PT, Gibbs SD, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2009). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 10, 2443 - .
    • Gibbs SDJ, De Cruz M, Sattianayagam PT, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2009). Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment..
    • Gibbs SDJ, Gillmore JD, Sattianayagam PT, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD (2009). In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.
    • Sattianayagam PT, Gibbs SDJ, Gilbertson J, Hawkins PN, Lachmann HJ (2009). Amyloid in a liver biopsy-what does it indicate?. J GASTROEN HEPATOL, 24, A276 - A276.
    • Kuemmerle-Deschner J, Lachmann HJ, Kone-Paut I, Leslie K, Hachulla E, Quartier P, Krammer G, Patel N, Lheritier K, Preiss R, Hawkins PN (2009). One-year results of canakinumab (ACZ885), a fully human anti-IL-1beta monoclonal antibody in patients with cryopyrin-associated periodic fever syndrome (CAPS). SWISS MED WKLY, 139(31-32), 4S - 4S.
    • Wechalekar A, Hawkins PN, Wassef NJ, Gillmore ND, Lachmann HJ, Morris J, Thomas M, Bradwell AR, Mead G (2009). Monoclonal Protein Detection in AL Amyloidosis Revisited: Analysis of 642 Patients. CLIN LYMPHOMA MYELOM, 9, S49 - S49.
    • Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, Hawkins PN, Palladini G (2009). A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response. CLIN LYMPHOMA MYELOM, 9, S51 - S51.
    • Gibbs SD, Sattianayagam PT, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2009). Solid Organ Transplantation in AL Amyloidosis: Lessons Learned and Its Current Role. CLIN LYMPHOMA MYELOM, 9, S71 - S71.
    • Lachmann HJ, Hawkins PN (2009). Developments in the scientific and clinical understanding of autoinflammatory disorders.. Arthritis Research and Therapy, 11(1), 212 - .
    • Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN (2009). Use of canakinumab in the cryopyrin-associated periodic syndrome.. New England Journal of Medicine, 360(23), 2416 - 2425.
    • Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T (2009). In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.. Journal of Experimental Medicine, 260(5), 1029 - 1036.
    • Wechalekar AD, Offer M, Gillmore JD, Hawkins PN, Lachmann HJ (2009). Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.. Nature Clinical Practice Cardiovascular Medicine, 6(2), 128 - 133.
    • Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009). Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.. Journal of the American Society of Nephrology, 20(2), 444 - 451.
    • Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, Lachmann HJ, Lang U, Kovarik J (2009). Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation.. Nephrology Dialysis Transplantation, 24(2), 676 - 678.
    • Gibbs SDJ, Sattianayagam PT, Gillmore JD, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD (2009). Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.

    2008

    • Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD (2008). AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112(10), 4009 - 4016.
    • Schreiber BE, Lachmann HJ, Mackworth-Young CG (2008). Possible familial Mediterranean fever in a Caucasian patient with systemic lupus erythematosus.. Lupus, 17(8), 752 - 753.
    • Lachmann HJ, Wechalekar AD, Gillmore JD (2008). High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.. New England Journal of Medicine, 358(1), 92 - 93.
    • Lachmann HJ, Goodman HJB, Gillmore JD, Wechalekar A, Rowczenio DM, Bybee A, Hawkins PN (2008). Comparison of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant.
    • Offer M, Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2008). AL amyloidosis in the elderly: A review of 330 patients.
    • Lachmann HJ, Kone-Paut I, Kummerle-Deschner J, Leslie K, Hachulla E, Gitton X, Patel N, Widmer A, Hawkins P (2008). Efficacy and Safety of Canakinumab (ACZ885), A Fully Human Anti-interleukin 1 beta Antibody, in Cryopyrin Associated Periodic Fever Syndrome: Results of a Multicenter, Randomized, Double-blind, Phase III Study.
    • Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, Hawkins PN, Palladini G (2008). Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.
    • Gibbs SDJ, Sattianayagam PT, Lachmann HJ, Offer M, Gillmore JD, Hawkins PN, Wechalekar A (2008). Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.
    • Scully C, Hodgson TA, Lachmann H (2008). Auto-inflammatory syndromes and oral health. Oral Diseases, 14(8), 690 - 699.
    • Scully C, Sweeney M, Hodgson TA, Lachmann H (2008). Periodic syndromes presenting with recurrent oral ulceration.
    • Lachmann HJ (2008). The hereditary periodic fever syndromes - models to understand inflammation.
    • Rowczenio D, Russell TL, Bybee A, Hawkins PN, Lachmann HJ (2008). Characterisation of the genes associated with hereditary periodic fevers syndromes in patients with AA amyloidosis of undetermined aetiology.
    • Rowczenio D, Russell TL, Bybee A, Hawkins PN, Lachmann HJ (2008). Experience of a dedicated fever clinic and laboratory service at the UK National Amyloidosis Centre (NAC).
    • Russell T, Bybee A, Hawkins PN, Lindley KJ, Rowczenio DM, Lachmann HJ (2008). MVK mutations in unusual populations.
    • Lachmann HJ, Wechalekar AD, Gillmore JD (2008). High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.. N Engl J Med, 358(1), 91 - 92.
    • Hamour IM, Lachmann HJ, H J P, M B, M M H, P N B, N R (2008). Heart transplantation for homozygous familial transthyretin (TTR)V1221 cardiac amyloidosis.. American Journal of Transplantation, 8(5), 1056 - 1059.
    • Wechalekar AD, Lachmann HL, Offer M, Hawkins PN, Gillmoe JD (2008). Efficacy of bortezomib in systemic AL amyloidosis with relapse/refractory clonal disease.. Haematologica, 93(2), 295 - 298.

    2007

    • Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2007). Abnormal NT-ProBNP in AL amyloidosis patients without cardiac involvement at diagnosis - A predictor of subsequent cardiac involvement.
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2007). A profile of 44 long term survivors (> 10yrs) with AL amyloidosis.
    • Lachmann HJ, Hawkins PN (2007). Eprodisate in AA amyloidosis - Reply. NEW ENGL J MED, 357(11), 1154 - 1154.
    • Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007). Natural history and outcome in systemic AA amyloidosis. New England Journal of Medicine, 356(23), 2361 - 2371. doi:10.1056/NEJMoa070265
    • Dember LM, Hawkins PN, Bouke PC, Hazenberg MD, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann H, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M (2007). Eprodisate for the treatment of AA Amyloidosis. New England Journal of Medicine, 356(23), 2349 - 2360. doi:10.1056/NEJMoa065644
    • Hasserjian RP, Goodman HJB, Lachmann HJ, Muzikansky A, Hawkins PN (2007). Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis. Histopathology, 50(5), 567 - 573.
    • Offer M, Wechalekar AD, Gilmore JD, Lachmann HJ, Hawkins PN (2007). Natural history and outcome of amyloidosis in the elderly.
    • Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2007). NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy.
    • Borg FA, Lachmann HJ, Ehrenstein MR (2007). Treatment resistant HLA-B27 associated juvenile idiopathic arthritis mimicking systemic juvenile arthritis: Management of secondary systemic amyloidosis and the failure of ANTI-TNF alpha therapy.
    • Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2007). Safety and efficacy of risk adapted cyclophosphamide,thalidomide and dexamethasone in systemic AL amyloidosis. Blood, 109(2), 457 - 464. doi:10.1182/blood-2006-07-035352
    • Lachmann HJ, Hawkins PN (2007). Fitzpatrick's Dermatology in General Medicine. Chapter 109 Amyloidosis and the Skin. In (Ed.), (pp. - ). : .
    • Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2007). Clinical profile and treatment outcome in 103 patients with al amyloidosis associated with IGM paraproteinaemia.

    2006

    • Offer M, Wechalekar AD, Gillmore JD, Lachmann HJ, Hawkins PN (2006). Natural history and outcome of amyloidosis in the elderly.
    • Rowczenio DM, Lachmann HJ, Gillmore JD, Wechalekar AD, Gilbertson JA, Goodman HJB, Hawkins PN, Bybee A (2006). Screening for patients with hereditary systemic amyloidosis.
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Offer M, Joshi JJ, Hawkins PN (2006). NT-ProBNP in AL amyloidosis: changes after chemotherapy and association with survival.
    • Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O'Grady J, Heaton ND, Pepys MB, Hawkins PN (2006). Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant, 6(10), 2342 - 2347. doi:10.1111/j.1600-6143.2006.01507.x
    • Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Hawkins PN, Roberts PF, Grattan CE (2006). The phenotype of patients with cryopyrin-associated periodic syndrome and response to treatment with anti-interleukin 1 (anakinira).
    • Lachmann HJ, Jung T, Bobadilla M, Felix SD, Woessner R, Leslie KS, Offer M, Gratten CE, Hawkins PN, Wright TM (2006). Treatment of muckle wells syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885) - Initial results from a proof of concept study.
    • Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyturk M, Akar S, Tunca M, Hawkins PN (2006). Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.. Rheumatology, 45(6), 746 - 750. doi:10.1093/rheumatology/kei279
    • Lachmann HJ, Goodman HJ, Andrews PA, Gallagher H, Marsh J, Breuer S, Rowczenio DM, Bybee A, Hawkins PN (2006). AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases.. Arthritis Rheum, 54(6), 2010 - 2014. doi:10.1002/art.21901
    • Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN (2006). Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107(3), 1227 - 1229. doi:10.1182/blood-2005-08-3253
    • Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN (2006). Outcome of autologous transplantation for AL amyloidosis in the UK. British Journal of Haematology, 134(4), 417 - 425.
    • Lachmann HJ, Hawkins PN (2006). Amyloidosis and the Lung. Chronic Respiratory Disease, 3, 203 - 214.
    • Lachmann HJ, Hawkins PN (2006). Systemic Amyloidosis. Current Opinion in Pharmacology, 6(2), 214 - 220.
    • Lachmann HJ (2006). The inherited fever syndromes. Climb Update, 3(1), 24 - .
    • Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN (2006). Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol, 142(12), 1591 - 1597.
    • Gillmore JD, Offer M, Lachmann HJ, Goodman HJ, Tennent GA, Gallimore JR, Pepys MB, Hawkins PN (2006). A pilot study of the tolerability, safety and efficacy of CPHPC in patients with systemic amyloidosis.
    • Connolly JO, Gillmore JD, Lachmann HJ, Davenport A, Hawkins PN, Woolfson RG (2006). Renal amyloidosis in intravenous drug users.. QJM, 99(11), 737 - 742. doi:10.1093/qjmed/hcl092
    • Hawkins PN, Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Gillmore JD (2006). Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis.
    • Bybee A, Lachmann HJ, Rowczenio DM, Russell T, Goodman HJB, Hawkins PN (2006). Genes associated with inherited periodic fever syndromes (IPFS) in patients with AA amyloidosis of undetermined aetiology.
    • Lachmann HJ, Goodman HJB, Joshi JJ, Gilbertson JA, Gillmore JD, Bybee A, Rowczenio DM, Hawkins PN (2006). Characterisation of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant.

    2005

    • Offer M, Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Bradwell AR, Hawkins PN (2005). Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay..
    • Gillmore JD, Wechalekar AD, Goodmarn HJB, Lachmann HJ, Offer M, Joshi J, Hawkins RN (2005). Cardiac followed by autologous stem cell transplantation for systemic AL amyloidosis..
    • Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN (2005). Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis..
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Goodman HJB, Offer M, Hawkins PN (2005). The role of renal transplantation in systemic AL amyloidosis..
    • Stangou AJ, Rela M, O'Grady JG, Heneghan M, Mathias CJ, Muiesan P, Sizer L, Wendon J, Gillmore JD, Lachmann H, Goodman HJ, Tennent G, Brennan S, Pepys MB, Hawkins PN, Heaton ND (2005). Fibrinogen Aα-chain Amyloidosis: Clinical features and the role of combined liver and kidney transplantation.. Hepatology, 42 (Supplement), 458A - .
    • Stangou AJ, Lachmann HL, Goodman HJB, Bybee A, Rowzcenio D, Tennent G, Brennan SO, O'Grady JG, Heaton ND, Rela M, Hawkins PN (2005). Fibrinogen A a-chain amyloidosis: clinical features and outcome after hepatorenal or solitary kidney transplantation.. In Grateau G, Kyle RA, Skinner M (Ed.), Amyloid and Amyloidosis (pp. 312 - 314). : CRC Press.
    • Meyer A, Lachmann HJ, Webster AD, Burns A, Thway K (2005). Hypercalcaemia in a patient with common variable immunodeficiency and renal granulomas.. American Journal of Kidney Diseases, 45(5), e90 - e93.
    • Fisher BA, Lachmann HJ, Rowczenio D, Goodman HJB, Bhalara S, Hawkins PN (2005). Colchicine responsive periodic fever syndrome associated with pyrin I591T.. Annals of the Rheumatic Diseases, 64(9), 1384 - 1385.
    • Dinc A, Erdem H, Rowczenio D, Simsek I, Pay S, Bahce M, Lachmann H (2005). Autosomal dominant periodic fever with AA amyloidosis: tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Turkish family. Journal of Nephrology, 18(5), 626 - 629.
    • Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN (2005). Clinical profile and treatment outcome in 92 patients with AL amyloidosis associated with IgM paraproteinaemia..

    2004

    • Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF (2004). Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun, 5(4), 289 - 293.
    • Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN (2004). Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis..
    • Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P (2004). Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade.. Rheumatology, 43(5), 669 - 672.
    • Bird J, Cavenagh J, Hawkins P, Lachmann H, Mehta A, Samson D (2004). Guidelines on the diagnosis and management of AL amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 125(6), 681 - 700.
    • Hawkins PN, Lachmann HJ, Aganna E, McDermott MF (2004). Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.. Arthritis and Rheumatism, 50(2), 607 - 612.
    • Haagsma EB, Hawkins PN, Benson MD, Lachmann HJ, Bybee A, Hazenberg BP (2004). Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families.. Amyloid, 11(1), 44 - 49.
    • Hu MTM, Gabriel CM, Lachmann HJ, King R, Hawkins PN, Ginsberg L (2004). A faint in the emergency department (due to primary systemic amyloidosis neuropathy).. Practical Neurology, 4(2), 104 - 109. doi:10.1111/j.1474-7766.2004.06-211.x

    2003

    • Aganna E, Hawkins PN, Lachmann HJ, Bybee A, Karenko L, Pettersson T, Ranki A, Hitman GA, Woo P, McDermott MF (2003). The spectrum and frequency of MEFV, TNFRSF1A, and NALP3/CIAS1/PYPAF1 mutations in patients with AA amyloidosis associated with systemic inflammation..
    • Lachmann HJ, McDermott MF, Hawkins PN (2003). AA amyloidosis complicating the hereditary periodic fever syndromes..
    • Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, Bidwell JL, Castaner JL, Whiteford ML, Janssens-Korpola PL, Manna R, Powell RJ, Woo P, Solis P, Minden K, Frenkel J, Yague J, Mirakian RM, Hitman GA, McDermott MF (2003). Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum., 48(9), 2632 - 2644.
    • Lachmann HJ, Hawkins PN (2003). Novel pharmacological strategies in amyloidosis. NEPHRON CLINICAL PRACTICE, 94(4), c85 - c88.
    • Myers B, Lachmann H, Russell NH (2003). Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement. British Journal of Haematology, 121(5), 816 - 817.
    • Hawkins PN, Lachmann HJ, McDermott MF (2003). Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New England Journal of Medicine, 348(25), 2583 - 2584. doi:10.1056/NEJM200306193482523
    • Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN (2003). Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol, 122(1), 78 - 84. doi:10.1046/j.1365-2141.2003.04433.x
    • Lachmann HJ, Hawkins PN (2003). Diagnosis and management of the inherited periodic fever syndromes. CPD Bulletin Immunology and Allergy, 3, 16 - 19.

    2002

    • Lachmann HJ, Gillmore JD, Pepys MB, Hawkins PN (2002). Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy..
    • Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann H, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffman T, Jakob Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002). Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.. In Bock GR, Goode JA (Ed.), The nature and origin of amyloid fibrils (pp. 73 - 89). : Wiley.
    • Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF (2002). Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum., 46(9), 2445 - 2452.
    • Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB (2002). Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM, 95(4), 211 - 218.
    • Harrison CJ, Mazzullo H, Ross FM, Cheung KL, Gerrard G, Harewood L, Mehta A, Lachmann HJ, Hawkins PN, Orchard KH (2002). Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 117(2), 427 - 435.
    • Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002). Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417(6886), 254 - 259. doi:10.1038/417254a
    • Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Bradwell AR, Hawkins PN (2002). Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in 137 patients with systemic AL amyloidosis.. CLIN CHEM, 48(6), A165 - A165.
    • Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Hawkins PN (2002). Detection of monoclonal free light chains by nephelometry in 262 patients with systemic AL amyloidosis.. CLIN CHEM, 48(6), A164 - A165.
    • Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN (2002). Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med, 346(23), 1786 - 1791. doi:10.1056/NEJMoa013354
    • Lachmann HJ, Booth DR, Bybee A, Gillmore JD, Hawkins PN (2002). Frequency of hereditary systemic amyloidosis masquerading as immunoglobulin light chain, AL (primary), amyloidosis.. J AM SOC NEPHROL, 13, 39A - 39A.
    • Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002). Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis and Rheumatism, 46(10), 2571 - 2573.
    • Hawkins PN, Lachmann HJ, Pepys MB (2002). Hereditary amyloidosis - Reply. NEW ENGL J MED, 347(15), 1207 - 1207.
    • Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Hawkins PN (2002). Changes in the concentration of circulating free immunoglobulin light chains and outcome in systemic AL amyloidosis following chemotherapy..

    2001

    • Booth DR, Lachmann HJ, Gillmore JD, Booth SE, Hawkins PN (2001). Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. QJM, 94(10), 527 - 531.
    • Hawkins PN, Gallimore R, Smith L, Bradwell AR, Lachmann HJ (2001). Highly sensitive automated immunoassay for free immunoglobulin light-chains in diagnosis and follow up of AL amyloidosis. AMYLOID, 8, 70 - 71.
    • Gillmore JD, Apperley JF, Lachmann HJ, Barrett AJ, Madhoo S, Pepys MB, Hawkins PN (2001). Combination chemotherapy for systemic AL amyloidosis. AMYLOID, 8, 72 - 73.
    • Lachmann HJ, Hawkins PN (2001). Amyloidosis:rheumatic disease and amyloid;clinical features and treatment. In Adu D, Emery P, Madaio MP (Ed.), Rheumatology and the Kidney (pp. 322 - 348). : Oxford University Press.
    • Lachmann HJ, Hawkins PN (2001). Amyloidosis:Pathogenesis and Diagnosis. In Adu D, Emery P, Madaio MP (Ed.), Rheumatology and the Kidney (pp. 305 - 321). : Oxford University Press.
    • Nardin R, Lachmann H (2001). Familial amyloid polyneuropathy: presentation, diagnosis and treatment. J CLIN NEUROMUSC DIS, 2, 221 - 226.
    • Sinha MK, Lachmann HJ, Kuriakose B, Abdulla AK, Aggarwal RK (2001). An unusual cause of progressive heart failure. The Lancet, 357(9267), 1498 - .
    • Joshi J, Lachmann HJ, Morris R, Hawkins PN (2001). A comparison of ECG and echocardiographc findings in 500 patients attending an amyloidosis clinic. AMYLOID, 8, 161 - 162.
    • Gilbertson JA, Bahru Y, Nicholas J, Bridger J, Spittle M, Rylance PB, Odum J, Jackson MA, Lachmann HJ, Booth DR, Booth SE, Hawkins PN (2001). Retrospective immunohistochemical review of patients diagnosed with systemic amyloidosis in a single British general hospital between 1990 and 2000. AMYLOID, 8, 161 - 161.
    • Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Hawkins PN (2001). Hereditary systemic amyloidosis due to variant fibrinogen A alpha-chain is unexpectedly frequent in the British population. AMYLOID, 8, 151 - 151.

    2000

    • Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, Soytürk M, Akar S, Pepys MB, Tunca M, Hawkins PN (2000). The genetic basis of autosomal dominant familial Mediterranean fever. QJM, 93(4), 217 - 221.
    • Hasserjian RP, Lachmann HJ, Gillmore JD, Hawkins PN (2000). Correlation of bone marrow findings with organ distribution and amyloid burden in 103 patients with AL amyloidosis.. BLOOD, 96(11), 157A - 157A.
    • Lachmann HJ, Booth DR, Bybee A, Hawkins PN (2000). Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese-Taiwanese family. Human Mutation, 16(2), 180 - .

    1999

    • Lachmann HJ, Griffiths MH, Hoffbrand BI (1999). Kidney Disorders. In Geraint James D, Zumla A (Ed.), The Granulomatous Disorders (pp. 528 - 539). : Cambridge University Press.

    1998

    • Woolfson RG, Lachmann H (1998). Improvement in renal cholesterol emboli syndrome after simvastatin. The Lancet, 351(9112), 1331 - 1332.

    • Tennent GA, Gillmore JD, Lachmann HJ, Rowczenio D, Weldon M, Bybee AJ, Gilbertson J, Hamilton DV, Ball RY, Packman L, Hawkins PN, Pepys MB (). Heterozygous gelsolin Asp187Asn causes hereditary renal amyloidosis. , , - .
    • Scott IC, Hajela V, Hawkins PN, Lachmann HJ (). A Case Series and Systemic Review of Anakinra and Immunosupression in Idiopathic Recurrent Pericarditis. Journal of Cardiology Cases, , - .